Corient Private Wealth LP Reduces Amgen Position After Share Sale
Corient Private Wealth LP reduced its Amgen holding to 466,785 shares after selling 84,082 during the period. Tower View Wealth Management bought additional shares to total 82 worth $29,000, and Evergreen Advisors added a new stake worth about $37,000. Institutional investors hold 76.50%. An Amgen/AZ drug combo showed survival benefit in a lung cancer study, but Amgen shares sold off after Novartis reported disappointing pelacarsen trial results.